Earlier this year, the Governors of the Inter-American Development Bank (IDB) met in Mendoza, Argentina to hear the side of Dyogo Oliveira, Minister of Planning, Development, and Management. For years, Oliveira wanted the surrounding countries to change their opinions about private investments in national infrastructure projects.
In countries that have free markets, this seems like a no-brainer, but that’s not the case if some countries in Central and South America. Recently, that has been changing, but for Oliveira and his supporters, it’s not improving fast enough. During the meeting, Oliveira pointed out all the positivity and advancements they could make if the IDB supported private investments.
The most important thing he pointed out was the increase of completed infrastructure projects in Brazil. It’s just common sense that private investments would allow governments and contractors to find funding much more comfortable and quicker than traditional sources. Also, supporting private investments would mean changing their entire infrastructure. Visit infomoney.com to know more about Montoro Jens.
If they could agree to create financial guarantee mechanisms, they would be capable of leveraging hundreds of private investments that they could use in infrastructure projects all over Latin America. In Oliveira’s words, the IDB should promote already-completed studies that show how private investments could be a more efficient solution for project risk management.
Oliveira is not the only one currently supporting private investments. Luis Caputo, the Finance Minister and Chairman of the Bank’s Board of Governors, agrees with Oliveira proposal. There’s also the fact that many of Brazil’s investments come from Spain.
The man reporting on this year’s meeting was Felipe Montoro. Felipe MontoroJens spoke with many attendees to get the most accurate facts possible. From his reports, things look like they could be in favor of Oliveira and his supporters. Visit :http://www.consultasocio.com/q/sa/felipe-montoro-jens
Although he is not a household name, Clay Siegall is one of the most important figures in modern cancer research today. After a career spanning more than three decades, Clay Siegall has become widely known as one of the founders in the field of cancer therapy known as antibody drug conjugates. This novel approach to the treatment of old forms of cancer that had not seen significant improvements in mortality over the preceding decades has led to phenomenal breakthroughs in the field. Today, antibody drug conjugates are a major part of second-line treatment for a wide variety of different cancer subtypes.
But it wasn’t always smooth sailing for the man who would go on to invent one of the most important advances in cancer therapy of the last century. While at pharmaceutical giant Bristol-Myers Squibb, Dr. Siegall found it increasingly difficult to pursue the lines of research that he wanted to. At the same time, the company was largely uninterested in disrupting its own markets. This meant that the disruptive cancer-fighting technologies that Dr. Siegall was developing were not a top priority for the company to bring to market.
As a result, Dr. Siegall founded his own company in 1998. On what amounts to a shoestring budget for such a massive undertaking, Dr. Siegall began operations with only a few other researchers that he had recruited away from Bristol-Myers Squibb. Facing bankruptcy in the year 1999, Dr. Siegall was just barely able to squeak by, getting a number of last-minute bridge loans from people who truly believe in the project that he was pursuing.
But a 2001 IPO allowed to company to raise over $1.2 billion. Ever since, Seattle Genetics, the company that Dr. Siegall founded, has been one of the major players in the target of cancer therapy research and development space. The company currently has more than 12 products in the development pipeline, and it is involved in many different partnerships with some of the biggest names in the pharmaceutical industry.
Dr. Siegall continues to prove that his vision had both merit and the ability to save lives. In doing so, he has become one of the undisputed champions of the targeted cancer therapy industry.